BioCardia, Inc.

NasdaqCM BCDA

BioCardia, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2024

BioCardia, Inc. EBIT Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

BioCardia, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -959.85%, a 25.59% change year over year.
BioCardia, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -1,289.92%.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NasdaqCM: BCDA

BioCardia, Inc.

CEO	Dr. Peter A. Altman Ph.D.
IPO Date	Nov. 13, 1996
Location	United States
Headquarters	320 Soquel Way
Employees	16
Sector	Healthcare
Industries Biotechnology

Description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Key trends

Past 5 years